Antisense And Rnai Therapeutics Market
Antisense & RNAi Therapeutics Market Forecasts to 2030 - Global Analysis By Route of Administration (Subcutaneous Route, Intravenous Route, Pulmonary Delivery, Intrathecal Route, Intraperitoneal Injection and Other Routes of Administration), Indication (Autosomal Dominant Disease, Autosomal Recessive Disease, Chromosomal Disease and Other Indications), Technology, Application and By Geography
|
Years Covered |
2021-2030 |
|
Estimated Year Value (2023) |
US $1.66 BN |
|
Projected Year Value (2030) |
US $3.90 BN |
|
CAGR (2023 - 2030) |
13% |
|
Regions Covered |
North America, Europe, Asia Pacific, South America, and Middle East & Africa |
|
Countries Covered |
US, Canada, Mexico, Germany, UK, Italy, France, Spain, Japan, China, India, Australia, New Zealand, South Korea, Rest of Asia Pacific, South America, Argentina, Brazil, Chile, Middle East & Africa, Saudi Arabia, UAE, Qatar, and South Africa |
|
Largest Market |
Asia Pacific |
|
Highest Growing Market |
North America |
According to Stratistics MRC, the Global Antisense & RNAi Therapeutics Market is accounted for $1.66 billion in 2023 and is expected to reach $3.90 billion by 2030 growing at a CAGR of 13.0% during the forecast period. Antisense therapy is the selective and sequence-specific inhibition of gene expression by single-stranded DNA oligonucleotides. It is used to treat amyotrophic lateral sclerosis and Huntington's and Alzheimer's disease. On the other hand, RNA interference (RNAi) therapy is triggered by double-stranded RNA (dsRNA) and causes sequence-specific ribonucleic acid (mRNA) degradation of single-stranded target RNAs in response to dsRNA. RNAi has applications in treating a wide range of conditions, including viral infections, neurodegenerative diseases, and certain cancers.
According to the article published by the American Association for the Advancement of Science in July 2023, an antisense therapy developed by UMass Chan Medical School and RUSH University Medical Center is found useful in restoring production of the protein FMRP in cell specimens taken from individuals suffering from fragile X syndrome.
Market Dynamics:
Driver:
Rising incidence of genetic disorders
Genetic disorders result from abnormalities in an individual's DNA, and traditional treatment options for these conditions are often limited. Antisense and RNA interference (RNAi) therapies offer a promising approach by targeting the underlying genetic causes of these disorders at the molecular level. Furthermore, the increasing prevalence of genetic disorders has prompted a surge in clinical trials and research efforts focusing on antisense and RNAi therapies. Successful trials and regulatory approvals further validate the potential of these treatments, driving market growth.
Restraint:
High cost of RNAi based drugs
The complex development process, involving advanced technologies and stringent regulatory requirements, contributes to elevated production costs. These expenses are often reflected in the pricing of RNAi therapeutics, limiting accessibility for patients and healthcare systems. Affordability challenges can impede widespread adoption, hindering the market's growth potential. As a result, it will hamper market growth.
Opportunity:
Rapid adoption of novel drug delivery and launch of RNA therapeutics
The advent of advanced drug delivery technologies has enhanced the efficacy and targeted delivery of antisense and RNA interference (RNAi) therapeutics, fostering their widespread adoption. Furthermore, the regulatory approval and successful market entry of RNA-based treatments have bolstered investor confidence and fuelled research and development initiatives. This convergence of technological advancements and regulatory milestones has created a favourable environment, propelling the Antisense & RNAi Therapeutics Market.
Threat:
Immune responses
When exogenous RNA molecules, such as those used in antisense and RNA interference (RNAi) therapies, are introduced into the body, they may activate the immune system. This can trigger innate immune responses, including the release of pro-inflammatory cytokines and the activation of immune cells. Also, the body's adaptive immune system may recognize the foreign RNA as a threat, leading to the production of antibodies against the therapeutic molecules.
Covid-19 Impact
The COVID-19 pandemic has had a mixed impact on the antisense and RNAi therapeutics markets. On one hand, the focus on mRNA vaccine development has accelerated RNA-based technology acceptance. However, disruptions in clinical trials, supply chains, and research activities have caused delays in the development and commercialization of anti-sense and RNAi therapies. While increased recognition of RNA technologies is a positive outcome, the industry faces challenges in adapting to the changing landscape, emphasising the importance of resilience and adaptability for continued growth in a post-pandemic era.
The RNA antisense segment is expected to be the largest during the forecast period
The RNA antisense segment is estimated to hold the largest share. This innovative therapeutic approach aims to treat diseases at the genetic level by inhibiting or modifying the production of disease-related proteins. RNA antisense technology holds promise for various applications, including treating genetic disorders, cancers, and viral infections. With its ability to precisely intervene in gene expression, RNA antisense represents a pivotal segment within the broader market, contributing to the development of targeted and personalised therapeutic solutions for a range of medical conditions.
The cancer segment is expected to have the highest CAGR during the forecast period
The cancer segment is anticipated to have lucrative growth during the forecast period. Antisense and RNA interference (RNAi) therapies are designed to selectively target and modulate the expression of genes associated with cancer, inhibiting tumour progression or promoting cancer cell death. This segment encompasses a diverse range of approaches, including personalised RNA treatments tailored to individual genetic profiles. Because of their targeted and precise nature, these treatments have the potential to alter oncology by tackling certain biological pathways and improving therapeutic efficacy while minimising side effects.
Region with largest share:
Asia Pacific commanded the largest market share during the extrapolated period owing to increased investment in research and development, the rising prevalence of chronic diseases, and a supportive regulatory environment. Key countries such as China, Japan, and India are at the forefront, with a focus on developing and commercialising novel RNA-based therapies. Furthermore, collaborations between local and global biotech firms, along with a growing awareness of personalised medicine, drive advancements.
Region with highest CAGR:
North America is expected to witness profitable growth over the projection period. The region, lead by the US, has made significant expenditures in pharmaceutical and biotechnology research, which has stimulated the development of novel RNA-based medicines. Favourable regulatory landscapes, strategic collaborations between industry stakeholders and a high prevalence of chronic diseases contribute to market expansion. It also has a well-established healthcare infrastructure, a proactive approach to personalised medicine, and prominent market players. North America is at the forefront of the development of antisense and RNAi treatments, making it a dynamic and significant player in the worldwide market.
Key players in the market
Some of the key players in the Antisense & RNAi Therapeutics Market include Alnylam Pharmaceuticals, Inc., Ionis Pharmaceuticals (Akcea Therapeutics, Inc.), Biogen Inc, Sarepta Therapeutics, Inc, Arbutus Biopharma, Silence Therapeutics, Isarna Therapeutics GmbH, Arrowhead Pharmaceuticals, Inc, Gene Signal International SA, Benitec Biopharma Ltd, Olix Pharmaceuticals, GSK plc, Sanofi, Bio-Path Holdings Inc, Antisense Therapeutics Limited., Quark Pharmaceuticals, Merck, Astellas Pharma Inc, Marina Biosciences and Dicerna Pharmaceuticals.
Key Developments:
In July 2023, Alnylam Pharmaceuticals, Inc. partnered with Roche; to develop and market, zilebesiran, investigational ribonucleic acid interference (RNAi) therapeutic to treat hypertension
In March 2023, OliX Pharmaceuticals, Inc. dosed the first patient in a Phase 1 clinical trial of an investigational RNAi therapeutic designed to treat age-related macular degeneration (AMD)
Routes of Administration Covered:
• Subcutaneous Route
• Intravenous Route
• Pulmonary Delivery
• Intrathecal Route
• Intraperitoneal Injection
• Other Routes of Administration
Indications Covered:
• Autosomal Dominant Disease
• Autosomal Recessive Disease
• Chromosomal Disease
• Other Indications
Technologies Covered:
• RNA Antisense
• RNA Interference
Applications Covered:
• Ocular Disorders
• Respiratory Disorders
• Cardio metabolic & Renal Disorders
• Cancer
• Neurodegenerative Disorders
• Infectious Diseases
• Genetic Disorders
• Skin Diseases
• Other Applications
Regions Covered:
• North America
o US
o Canada
o Mexico
• Europe
o Germany
o UK
o Italy
o France
o Spain
o Rest of Europe
• Asia Pacific
o Japan
o China
o India
o Australia
o New Zealand
o South Korea
o Rest of Asia Pacific
• South America
o Argentina
o Brazil
o Chile
o Rest of South America
• Middle East & Africa
o Saudi Arabia
o UAE
o Qatar
o South Africa
o Rest of Middle East & Africa
What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements
Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options:
• Company Profiling
o Comprehensive profiling of additional market players (up to 3)
o SWOT Analysis of key players (up to 3)
• Regional Segmentation
o Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances
Table of Contents
1 Executive Summary
2 Preface
2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
2.4.1 Data Mining
2.4.2 Data Analysis
2.4.3 Data Validation
2.4.4 Research Approach
2.5 Research Sources
2.5.1 Primary Research Sources
2.5.2 Secondary Research Sources
2.5.3 Assumptions
3 Market Trend Analysis
3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Technology Analysis
3.7 Application Analysis
3.8 Emerging Markets
3.9 Impact of Covid-19
4 Porters Five Force Analysis
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry
5 Global Antisense & RNAi Therapeutics Market, By Route of Administration
5.1 Introduction
5.2 Subcutaneous Route
5.3 Intravenous Route
5.4 Pulmonary Delivery
5.5 Intrathecal Route
5.6 Intraperitoneal Injection
5.7 Other Routes of Administration
6 Global Antisense & RNAi Therapeutics Market, By Indication
6.1 Introduction
6.2 Autosomal Dominant Disease
6.3 Autosomal Recessive Disease
6.4 Chromosomal Disease
6.5 Other Indications
7 Global Antisense & RNAi Therapeutics Market, By Technology
7.1 Introduction
7.2 RNA Antisense
7.3 RNA Interference
8 Global Antisense & RNAi Therapeutics Market, By Application
8.1 Introduction
8.2 Ocular Disorders
8.3 Respiratory Disorders
8.4 Cardio metabolic & Renal Disorders
8.5 Cancer
8.6 Neurodegenerative Disorders
8.7 Infectious Diseases
8.8 Genetic Disorders
8.9 Skin Diseases
8.10 Other Applications
9 Global Antisense & RNAi Therapeutics Market, By Geography
9.1 Introduction
9.2 North America
9.2.1 US
9.2.2 Canada
9.2.3 Mexico
9.3 Europe
9.3.1 Germany
9.3.2 UK
9.3.3 Italy
9.3.4 France
9.3.5 Spain
9.3.6 Rest of Europe
9.4 Asia Pacific
9.4.1 Japan
9.4.2 China
9.4.3 India
9.4.4 Australia
9.4.5 New Zealand
9.4.6 South Korea
9.4.7 Rest of Asia Pacific
9.5 South America
9.5.1 Argentina
9.5.2 Brazil
9.5.3 Chile
9.5.4 Rest of South America
9.6 Middle East & Africa
9.6.1 Saudi Arabia
9.6.2 UAE
9.6.3 Qatar
9.6.4 South Africa
9.6.5 Rest of Middle East & Africa
10 Key Developments
10.1 Agreements, Partnerships, Collaborations and Joint Ventures
10.2 Acquisitions & Mergers
10.3 New Product Launch
10.4 Expansions
10.5 Other Key Strategies
11 Company Profiling
11.1 Alnylam Pharmaceuticals, Inc.
11.2 Ionis Pharmaceuticals (Akcea Therapeutics, Inc.)
11.3 Biogen Inc.
11.4 Sarepta Therapeutics, Inc.
11.5 Arbutus Biopharma
11.6 Silence Therapeutics
11.7 Isarna Therapeutics GmbH
11.8 Arrowhead Pharmaceuticals, Inc.
11.9 Gene Signal International SA
11.10 Benitec Biopharma Ltd
11.11 Olix Pharmaceuticals
11.12 GSK plc
11.13 Sanofi
11.14 Bio-Path Holdings Inc
11.15 Antisense Therapeutics Limited.
11.16 Quark Pharmaceuticals
11.17 Merck
11.18 Astellas Pharma Inc
11.19 Marina Biosciences
11.20 Dicerna Pharmaceuticals
List of Tables
1 Global Antisense & RNAi Therapeutics Market Outlook, By Region (2021-2030) ($MN)
2 Global Antisense & RNAi Therapeutics Market Outlook, By Route of Administration (2021-2030) ($MN)
3 Global Antisense & RNAi Therapeutics Market Outlook, By Subcutaneous Route (2021-2030) ($MN)
4 Global Antisense & RNAi Therapeutics Market Outlook, By Intravenous Route (2021-2030) ($MN)
5 Global Antisense & RNAi Therapeutics Market Outlook, By Pulmonary Delivery (2021-2030) ($MN)
6 Global Antisense & RNAi Therapeutics Market Outlook, By Intrathecal Route (2021-2030) ($MN)
7 Global Antisense & RNAi Therapeutics Market Outlook, By Intraperitoneal Injection (2021-2030) ($MN)
8 Global Antisense & RNAi Therapeutics Market Outlook, By Other Routes ofAdministration (2021-2030) ($MN)
9 Global Antisense & RNAi Therapeutics Market Outlook, By Indication (2021-2030) ($MN)
10 Global Antisense & RNAi Therapeutics Market Outlook, By Autosomal Dominant Disease (2021-2030) ($MN)
11 Global Antisense & RNAi Therapeutics Market Outlook, By Autosomal Recessive Disease (2021-2030) ($MN)
12 Global Antisense & RNAi Therapeutics Market Outlook, By Chromosomal Disease (2021-2030) ($MN)
13 Global Antisense & RNAi Therapeutics Market Outlook, By Other Indications (2021-2030) ($MN)
14 Global Antisense & RNAi Therapeutics Market Outlook, By Technology (2021-2030) ($MN)
15 Global Antisense & RNAi Therapeutics Market Outlook, By RNA Antisense (2021-2030) ($MN)
16 Global Antisense & RNAi Therapeutics Market Outlook, By RNA Interference (2021-2030) ($MN)
17 Global Antisense & RNAi Therapeutics Market Outlook, By Application (2021-2030) ($MN)
18 Global Antisense & RNAi Therapeutics Market Outlook, By Ocular Disorders (2021-2030) ($MN)
19 Global Antisense & RNAi Therapeutics Market Outlook, By Respiratory Disorders (2021-2030) ($MN)
20 Global Antisense & RNAi Therapeutics Market Outlook, By Cardio metabolic & Renal Disorders (2021-2030) ($MN)
21 Global Antisense & RNAi Therapeutics Market Outlook, By Cancer (2021-2030) ($MN)
22 Global Antisense & RNAi Therapeutics Market Outlook, By Neurodegenerative Disorders (2021-2030) ($MN)
23 Global Antisense & RNAi Therapeutics Market Outlook, By Infectious Diseases (2021-2030) ($MN)
24 Global Antisense & RNAi Therapeutics Market Outlook, By Genetic Disorders (2021-2030) ($MN)
25 Global Antisense & RNAi Therapeutics Market Outlook, By Skin Diseases (2021-2030) ($MN)
26 Global Antisense & RNAi Therapeutics Market Outlook, By Other Applications (2021-2030) ($MN)
27 North America Antisense & RNAi Therapeutics Market Outlook, By Country (2021-2030) ($MN)
28 North America Antisense & RNAi Therapeutics Market Outlook, By Route of Administration (2021-2030) ($MN)
29 North America Antisense & RNAi Therapeutics Market Outlook, By Subcutaneous Route (2021-2030) ($MN)
30 North America Antisense & RNAi Therapeutics Market Outlook, By Intravenous Route (2021-2030) ($MN)
31 North America Antisense & RNAi Therapeutics Market Outlook, By Pulmonary Delivery (2021-2030) ($MN)
32 North America Antisense & RNAi Therapeutics Market Outlook, By Intrathecal Route (2021-2030) ($MN)
33 North America Antisense & RNAi Therapeutics Market Outlook, By Intraperitoneal Injection (2021-2030) ($MN)
34 North America Antisense & RNAi Therapeutics Market Outlook, By Other Routes ofAdministration (2021-2030) ($MN)
35 North America Antisense & RNAi Therapeutics Market Outlook, By Indication (2021-2030) ($MN)
36 North America Antisense & RNAi Therapeutics Market Outlook, By Autosomal Dominant Disease (2021-2030) ($MN)
37 North America Antisense & RNAi Therapeutics Market Outlook, By Autosomal Recessive Disease (2021-2030) ($MN)
38 North America Antisense & RNAi Therapeutics Market Outlook, By Chromosomal Disease (2021-2030) ($MN)
39 North America Antisense & RNAi Therapeutics Market Outlook, By Other Indications (2021-2030) ($MN)
40 North America Antisense & RNAi Therapeutics Market Outlook, By Technology (2021-2030) ($MN)
41 North America Antisense & RNAi Therapeutics Market Outlook, By RNA Antisense (2021-2030) ($MN)
42 North America Antisense & RNAi Therapeutics Market Outlook, By RNA Interference (2021-2030) ($MN)
43 North America Antisense & RNAi Therapeutics Market Outlook, By Application (2021-2030) ($MN)
44 North America Antisense & RNAi Therapeutics Market Outlook, By Ocular Disorders (2021-2030) ($MN)
45 North America Antisense & RNAi Therapeutics Market Outlook, By Respiratory Disorders (2021-2030) ($MN)
46 North America Antisense & RNAi Therapeutics Market Outlook, By Cardio metabolic & Renal Disorders (2021-2030) ($MN)
47 North America Antisense & RNAi Therapeutics Market Outlook, By Cancer (2021-2030) ($MN)
48 North America Antisense & RNAi Therapeutics Market Outlook, By Neurodegenerative Disorders (2021-2030) ($MN)
49 North America Antisense & RNAi Therapeutics Market Outlook, By Infectious Diseases (2021-2030) ($MN)
50 North America Antisense & RNAi Therapeutics Market Outlook, By Genetic Disorders (2021-2030) ($MN)
51 North America Antisense & RNAi Therapeutics Market Outlook, By Skin Diseases (2021-2030) ($MN)
52 North America Antisense & RNAi Therapeutics Market Outlook, By Other Applications (2021-2030) ($MN)
53 Europe Antisense & RNAi Therapeutics Market Outlook, By Country (2021-2030) ($MN)
54 Europe Antisense & RNAi Therapeutics Market Outlook, By Route of Administration (2021-2030) ($MN)
55 Europe Antisense & RNAi Therapeutics Market Outlook, By Subcutaneous Route (2021-2030) ($MN)
56 Europe Antisense & RNAi Therapeutics Market Outlook, By Intravenous Route (2021-2030) ($MN)
57 Europe Antisense & RNAi Therapeutics Market Outlook, By Pulmonary Delivery (2021-2030) ($MN)
58 Europe Antisense & RNAi Therapeutics Market Outlook, By Intrathecal Route (2021-2030) ($MN)
59 Europe Antisense & RNAi Therapeutics Market Outlook, By Intraperitoneal Injection (2021-2030) ($MN)
60 Europe Antisense & RNAi Therapeutics Market Outlook, By Other Routes ofAdministration (2021-2030) ($MN)
61 Europe Antisense & RNAi Therapeutics Market Outlook, By Indication (2021-2030) ($MN)
62 Europe Antisense & RNAi Therapeutics Market Outlook, By Autosomal Dominant Disease (2021-2030) ($MN)
63 Europe Antisense & RNAi Therapeutics Market Outlook, By Autosomal Recessive Disease (2021-2030) ($MN)
64 Europe Antisense & RNAi Therapeutics Market Outlook, By Chromosomal Disease (2021-2030) ($MN)
65 Europe Antisense & RNAi Therapeutics Market Outlook, By Other Indications (2021-2030) ($MN)
66 Europe Antisense & RNAi Therapeutics Market Outlook, By Technology (2021-2030) ($MN)
67 Europe Antisense & RNAi Therapeutics Market Outlook, By RNA Antisense (2021-2030) ($MN)
68 Europe Antisense & RNAi Therapeutics Market Outlook, By RNA Interference (2021-2030) ($MN)
69 Europe Antisense & RNAi Therapeutics Market Outlook, By Application (2021-2030) ($MN)
70 Europe Antisense & RNAi Therapeutics Market Outlook, By Ocular Disorders (2021-2030) ($MN)
71 Europe Antisense & RNAi Therapeutics Market Outlook, By Respiratory Disorders (2021-2030) ($MN)
72 Europe Antisense & RNAi Therapeutics Market Outlook, By Cardio metabolic & Renal Disorders (2021-2030) ($MN)
73 Europe Antisense & RNAi Therapeutics Market Outlook, By Cancer (2021-2030) ($MN)
74 Europe Antisense & RNAi Therapeutics Market Outlook, By Neurodegenerative Disorders (2021-2030) ($MN)
75 Europe Antisense & RNAi Therapeutics Market Outlook, By Infectious Diseases (2021-2030) ($MN)
76 Europe Antisense & RNAi Therapeutics Market Outlook, By Genetic Disorders (2021-2030) ($MN)
77 Europe Antisense & RNAi Therapeutics Market Outlook, By Skin Diseases (2021-2030) ($MN)
78 Europe Antisense & RNAi Therapeutics Market Outlook, By Other Applications (2021-2030) ($MN)
79 Asia Pacific Antisense & RNAi Therapeutics Market Outlook, By Country (2021-2030) ($MN)
80 Asia Pacific Antisense & RNAi Therapeutics Market Outlook, By Route of Administration (2021-2030) ($MN)
81 Asia Pacific Antisense & RNAi Therapeutics Market Outlook, By Subcutaneous Route (2021-2030) ($MN)
82 Asia Pacific Antisense & RNAi Therapeutics Market Outlook, By Intravenous Route (2021-2030) ($MN)
83 Asia Pacific Antisense & RNAi Therapeutics Market Outlook, By Pulmonary Delivery (2021-2030) ($MN)
84 Asia Pacific Antisense & RNAi Therapeutics Market Outlook, By Intrathecal Route (2021-2030) ($MN)
85 Asia Pacific Antisense & RNAi Therapeutics Market Outlook, By Intraperitoneal Injection (2021-2030) ($MN)
86 Asia Pacific Antisense & RNAi Therapeutics Market Outlook, By Other Routes ofAdministration (2021-2030) ($MN)
87 Asia Pacific Antisense & RNAi Therapeutics Market Outlook, By Indication (2021-2030) ($MN)
88 Asia Pacific Antisense & RNAi Therapeutics Market Outlook, By Autosomal Dominant Disease (2021-2030) ($MN)
89 Asia Pacific Antisense & RNAi Therapeutics Market Outlook, By Autosomal Recessive Disease (2021-2030) ($MN)
90 Asia Pacific Antisense & RNAi Therapeutics Market Outlook, By Chromosomal Disease (2021-2030) ($MN)
91 Asia Pacific Antisense & RNAi Therapeutics Market Outlook, By Other Indications (2021-2030) ($MN)
92 Asia Pacific Antisense & RNAi Therapeutics Market Outlook, By Technology (2021-2030) ($MN)
93 Asia Pacific Antisense & RNAi Therapeutics Market Outlook, By RNA Antisense (2021-2030) ($MN)
94 Asia Pacific Antisense & RNAi Therapeutics Market Outlook, By RNA Interference (2021-2030) ($MN)
95 Asia Pacific Antisense & RNAi Therapeutics Market Outlook, By Application (2021-2030) ($MN)
96 Asia Pacific Antisense & RNAi Therapeutics Market Outlook, By Ocular Disorders (2021-2030) ($MN)
97 Asia Pacific Antisense & RNAi Therapeutics Market Outlook, By Respiratory Disorders (2021-2030) ($MN)
98 Asia Pacific Antisense & RNAi Therapeutics Market Outlook, By Cardio metabolic & Renal Disorders (2021-2030) ($MN)
99 Asia Pacific Antisense & RNAi Therapeutics Market Outlook, By Cancer (2021-2030) ($MN)
100 Asia Pacific Antisense & RNAi Therapeutics Market Outlook, By Neurodegenerative Disorders (2021-2030) ($MN)
101 Asia Pacific Antisense & RNAi Therapeutics Market Outlook, By Infectious Diseases (2021-2030) ($MN)
102 Asia Pacific Antisense & RNAi Therapeutics Market Outlook, By Genetic Disorders (2021-2030) ($MN)
103 Asia Pacific Antisense & RNAi Therapeutics Market Outlook, By Skin Diseases (2021-2030) ($MN)
104 Asia Pacific Antisense & RNAi Therapeutics Market Outlook, By Other Applications (2021-2030) ($MN)
105 South America Antisense & RNAi Therapeutics Market Outlook, By Country (2021-2030) ($MN)
106 South America Antisense & RNAi Therapeutics Market Outlook, By Route of Administration (2021-2030) ($MN)
107 South America Antisense & RNAi Therapeutics Market Outlook, By Subcutaneous Route (2021-2030) ($MN)
108 South America Antisense & RNAi Therapeutics Market Outlook, By Intravenous Route (2021-2030) ($MN)
109 South America Antisense & RNAi Therapeutics Market Outlook, By Pulmonary Delivery (2021-2030) ($MN)
110 South America Antisense & RNAi Therapeutics Market Outlook, By Intrathecal Route (2021-2030) ($MN)
111 South America Antisense & RNAi Therapeutics Market Outlook, By Intraperitoneal Injection (2021-2030) ($MN)
112 South America Antisense & RNAi Therapeutics Market Outlook, By Other Routes ofAdministration (2021-2030) ($MN)
113 South America Antisense & RNAi Therapeutics Market Outlook, By Indication (2021-2030) ($MN)
114 South America Antisense & RNAi Therapeutics Market Outlook, By Autosomal Dominant Disease (2021-2030) ($MN)
115 South America Antisense & RNAi Therapeutics Market Outlook, By Autosomal Recessive Disease (2021-2030) ($MN)
116 South America Antisense & RNAi Therapeutics Market Outlook, By Chromosomal Disease (2021-2030) ($MN)
117 South America Antisense & RNAi Therapeutics Market Outlook, By Other Indications (2021-2030) ($MN)
118 South America Antisense & RNAi Therapeutics Market Outlook, By Technology (2021-2030) ($MN)
119 South America Antisense & RNAi Therapeutics Market Outlook, By RNA Antisense (2021-2030) ($MN)
120 South America Antisense & RNAi Therapeutics Market Outlook, By RNA Interference (2021-2030) ($MN)
121 South America Antisense & RNAi Therapeutics Market Outlook, By Application (2021-2030) ($MN)
122 South America Antisense & RNAi Therapeutics Market Outlook, By Ocular Disorders (2021-2030) ($MN)
123 South America Antisense & RNAi Therapeutics Market Outlook, By Respiratory Disorders (2021-2030) ($MN)
124 South America Antisense & RNAi Therapeutics Market Outlook, By Cardio metabolic & Renal Disorders (2021-2030) ($MN)
125 South America Antisense & RNAi Therapeutics Market Outlook, By Cancer (2021-2030) ($MN)
126 South America Antisense & RNAi Therapeutics Market Outlook, By Neurodegenerative Disorders (2021-2030) ($MN)
127 South America Antisense & RNAi Therapeutics Market Outlook, By Infectious Diseases (2021-2030) ($MN)
128 South America Antisense & RNAi Therapeutics Market Outlook, By Genetic Disorders (2021-2030) ($MN)
129 South America Antisense & RNAi Therapeutics Market Outlook, By Skin Diseases (2021-2030) ($MN)
130 South America Antisense & RNAi Therapeutics Market Outlook, By Other Applications (2021-2030) ($MN)
131 Middle East & Africa Antisense & RNAi Therapeutics Market Outlook, By Country (2021-2030) ($MN)
132 Middle East & Africa Antisense & RNAi Therapeutics Market Outlook, By Route of Administration (2021-2030) ($MN)
133 Middle East & Africa Antisense & RNAi Therapeutics Market Outlook, By Subcutaneous Route (2021-2030) ($MN)
134 Middle East & Africa Antisense & RNAi Therapeutics Market Outlook, By Intravenous Route (2021-2030) ($MN)
135 Middle East & Africa Antisense & RNAi Therapeutics Market Outlook, By Pulmonary Delivery (2021-2030) ($MN)
136 Middle East & Africa Antisense & RNAi Therapeutics Market Outlook, By Intrathecal Route (2021-2030) ($MN)
137 Middle East & Africa Antisense & RNAi Therapeutics Market Outlook, By Intraperitoneal Injection (2021-2030) ($MN)
138 Middle East & Africa Antisense & RNAi Therapeutics Market Outlook, By Other Routes ofAdministration (2021-2030) ($MN)
139 Middle East & Africa Antisense & RNAi Therapeutics Market Outlook, By Indication (2021-2030) ($MN)
140 Middle East & Africa Antisense & RNAi Therapeutics Market Outlook, By Autosomal Dominant Disease (2021-2030) ($MN)
141 Middle East & Africa Antisense & RNAi Therapeutics Market Outlook, By Autosomal Recessive Disease (2021-2030) ($MN)
142 Middle East & Africa Antisense & RNAi Therapeutics Market Outlook, By Chromosomal Disease (2021-2030) ($MN)
143 Middle East & Africa Antisense & RNAi Therapeutics Market Outlook, By Other Indications (2021-2030) ($MN)
144 Middle East & Africa Antisense & RNAi Therapeutics Market Outlook, By Technology (2021-2030) ($MN)
145 Middle East & Africa Antisense & RNAi Therapeutics Market Outlook, By RNA Antisense (2021-2030) ($MN)
146 Middle East & Africa Antisense & RNAi Therapeutics Market Outlook, By RNA Interference (2021-2030) ($MN)
147 Middle East & Africa Antisense & RNAi Therapeutics Market Outlook, By Application (2021-2030) ($MN)
148 Middle East & Africa Antisense & RNAi Therapeutics Market Outlook, By Ocular Disorders (2021-2030) ($MN)
149 Middle East & Africa Antisense & RNAi Therapeutics Market Outlook, By Respiratory Disorders (2021-2030) ($MN)
150 Middle East & Africa Antisense & RNAi Therapeutics Market Outlook, By Cardio metabolic & Renal Disorders (2021-2030) ($MN)
151 Middle East & Africa Antisense & RNAi Therapeutics Market Outlook, By Cancer (2021-2030) ($MN)
152 Middle East & Africa Antisense & RNAi Therapeutics Market Outlook, By Neurodegenerative Disorders (2021-2030) ($MN)
153 Middle East & Africa Antisense & RNAi Therapeutics Market Outlook, By Infectious Diseases (2021-2030) ($MN)
154 Middle East & Africa Antisense & RNAi Therapeutics Market Outlook, By Genetic Disorders (2021-2030) ($MN)
155 Middle East & Africa Antisense & RNAi Therapeutics Market Outlook, By Skin Diseases (2021-2030) ($MN)
156 Middle East & Africa Antisense & RNAi Therapeutics Market Outlook, By Other Applications (2021-2030) ($MN)
List of Figures
RESEARCH METHODOLOGY
We at ‘Stratistics’ opt for an extensive research approach which involves data mining, data validation, and data analysis. The various research sources include in-house repository, secondary research, competitor’s sources, social media research, client internal data, and primary research.
Our team of analysts prefers the most reliable and authenticated data sources in order to perform the comprehensive literature search. With access to most of the authenticated data bases our team highly considers the best mix of information through various sources to obtain extensive and accurate analysis.
Each report takes an average time of a month and a team of 4 industry analysts. The time may vary depending on the scope and data availability of the desired market report. The various parameters used in the market assessment are standardized in order to enhance the data accuracy.
Data Mining
The data is collected from several authenticated, reliable, paid and unpaid sources and is filtered depending on the scope & objective of the research. Our reports repository acts as an added advantage in this procedure. Data gathering from the raw material suppliers, distributors and the manufacturers is performed on a regular basis, this helps in the comprehensive understanding of the products value chain. Apart from the above mentioned sources the data is also collected from the industry consultants to ensure the objective of the study is in the right direction.
Market trends such as technological advancements, regulatory affairs, market dynamics (Drivers, Restraints, Opportunities and Challenges) are obtained from scientific journals, market related national & international associations and organizations.
Data Analysis
From the data that is collected depending on the scope & objective of the research the data is subjected for the analysis. The critical steps that we follow for the data analysis include:
- Product Lifecycle Analysis
- Competitor analysis
- Risk analysis
- Porters Analysis
- PESTEL Analysis
- SWOT Analysis
The data engineering is performed by the core industry experts considering both the Marketing Mix Modeling and the Demand Forecasting. The marketing mix modeling makes use of multiple-regression techniques to predict the optimal mix of marketing variables. Regression factor is based on a number of variables and how they relate to an outcome such as sales or profits.
Data Validation
The data validation is performed by the exhaustive primary research from the expert interviews. This includes telephonic interviews, focus groups, face to face interviews, and questionnaires to validate our research from all aspects. The industry experts we approach come from the leading firms, involved in the supply chain ranging from the suppliers, distributors to the manufacturers and consumers so as to ensure an unbiased analysis.
We are in touch with more than 15,000 industry experts with the right mix of consultants, CEO's, presidents, vice presidents, managers, experts from both supply side and demand side, executives and so on.
The data validation involves the primary research from the industry experts belonging to:
- Leading Companies
- Suppliers & Distributors
- Manufacturers
- Consumers
- Industry/Strategic Consultants
Apart from the data validation the primary research also helps in performing the fill gap research, i.e. providing solutions for the unmet needs of the research which helps in enhancing the reports quality.
For more details about research methodology, kindly write to us at info@strategymrc.com
Frequently Asked Questions
In case of any queries regarding this report, you can contact the customer service by filing the “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929
Yes, the samples are available for all the published reports. You can request them by filling the “Request Sample” option available in this page.
Yes, you can request a sample with your specific requirements. All the customized samples will be provided as per the requirement with the real data masked.
All our reports are available in Digital PDF format. In case if you require them in any other formats, such as PPT, Excel etc you can submit a request through “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929
We offer a free 15% customization with every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.
We have 3 different licensing options available in electronic format.
- Single User Licence: Allows one person, typically the buyer, to have access to the ordered product. The ordered product cannot be distributed to anyone else.
- 2-5 User Licence: Allows the ordered product to be shared among a maximum of 5 people within your organisation.
- Corporate License: Allows the product to be shared among all employees of your organisation regardless of their geographical location.
All our reports are typically be emailed to you as an attachment.
To order any available report you need to register on our website. The payment can be made either through CCAvenue or PayPal payments gateways which accept all international cards.
We extend our support to 6 months post sale. A post sale customization is also provided to cover your unmet needs in the report.
Request Customization
We provide a free 15% customization on every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.
Note: This customization is absolutely free until it falls under the 15% bracket. If your requirement exceeds this a feasibility check will be performed. Post that, a quote will be provided along with the timelines.
WHY CHOOSE US ?
Assured Quality
Best in class reports with high standard of research integrity
24X7 Research Support
Continuous support to ensure the best customer experience.
Free Customization
Adding more values to your product of interest.
Safe & Secure Access
Providing a secured environment for all online transactions.
Trusted by 600+ Brands
Serving the most reputed brands across the world.
